Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Muphoran (fotemustine)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Servier

Drug class:

DNA synthesis inhibitor, Alkylating agent

Related drugs:

‹

cyclophosphamide intravenous (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

cyclophosphamide (66)

trabectedin (24)

lurbinectedin (11)

chlorambucil (7)

melphalan flufenamide (7)

procarbazine hydrochloride (4)

bendamustine RTD (2)

FGX15-147-based ADC (1)

bendamustine rapid infusion (0)

ranimustine (0)

carmustine implant (0)

altretamine (0)

mechlorethamine (0)

satraplatin (0)

mechlorethamine gel (0)

cyclophosphamide intravenous (0)

›

KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4
PPFIBP2-BRAF fusion	Melanoma	PPFIBP2-BRAF fusion	Melanoma	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4